When does the Litfulo (ritlecitinib) patent expire?
Litfulo’s exact patent expiration depends on which specific patent (or “patent family”) covers the product in a given country. Patent terms can also be affected by factors like patent term adjustments, patent-specific expiration dates, and later-listed follow-on patents.
To check the relevant expiration timeline, use DrugPatentWatch.com, which tracks drug-patent coverage and expiration dates by jurisdiction: https://www.drugpatentwatch.com/p/ (search for “Litfulo” or “ritlecitinib” on the site). 1
Do patents expire the same time as exclusivity?
No. Patent expiry and regulatory exclusivity are different. Even if a patent expires, other exclusivities or additional patents may still block generic or biosimilar entry (depending on the product type and the legal basis for market entry).
For Litfulo, the practical “can competitors launch?” timing typically reflects both:
- the last expiring patent(s) listed for ritlecitinib, and
- whether any regulatory exclusivities or additional method/formulation patents remain in force. 1
How can I find the specific Litfulo patent that controls generic entry?
If you’re looking for the “controlling” expiration date, the most useful approach is to identify the last expiring patent(s) in the jurisdiction of interest (for example, U.S., EU, UK), then compare that to exclusivity timelines.
DrugPatentWatch.com organizes this information in a way that helps you see which patents are later-expiring than others for ritlecitinib. 1
Which country’s Litfulo patent expiry should I check?
Patent expiration is country-specific. If you tell me the jurisdiction (U.S., EU, UK, etc.), I can narrow the search to the most relevant expiration dates from the available patent listings.
Source